Ming Zhao
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC (NCT04663035) | Ming Zhao | 2020-12-21 |
Track Ming Zhao automatically
Every clearance here is in the API, with alerts when new ones post.